Home › Funds › BOONE CAPITAL MANAGEMENT LLC › BMRN
BOONE CAPITAL MANAGEMENT LLC position in BMRN
BIOMARIN PHARMACEUTICAL INC · Health Care
BOONE CAPITAL MANAGEMENT LLC reported holding 583,219 shares of BMRN (BIOMARIN PHARMACEUTICAL INC) in its Q2 2026 13F filing — a position valued at US$33.4M, representing 7.81% of its reported portfolio and ranking #6 among its reported holdings. BOONE CAPITAL MANAGEMENT LLC has disclosed BMRN holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BOONE CAPITAL MANAGEMENT LLC's BMRN position evolved
BOONE CAPITAL MANAGEMENT LLC first disclosed a stake in BMRN in Q1 2025 at 327,279 shares (US$23.1M). The position peaked in Q2 2026 at 583,219 shares, worth US$33.4M. Across 6 filings, BOONE CAPITAL MANAGEMENT LLC increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 583,219 shares valued at US$33.4M — an increase of 35,348 shares quarter over quarter.. Notable position changes include a 37% increase in Q2 2025 (shares fell 1% over the following quarter), a 27% trim in Q3 2025 (shares rose 10% over the following quarter), a 33% increase in Q1 2026 (shares rose 1% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 327.28K | $23.14M | New |
| Q2 2025 | 447.45K | $24.60M | Add |
| Q3 2025 | 328.55K | $17.79M | Reduce |
| Q4 2025 | 411.88K | $24.48M | Add |
| Q1 2026 | 547.87K | $30.95M | Add |
| Q2 2026 | 583.22K | $33.37M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BMRN and 13F data
BMRN (BIOMARIN PHARMACEUTICAL INC) is a Health Care company. 27 other funds we track also report a position in BMRN — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$812.0M), Viking Global Investors (US$435.8M), VIKING GLOBAL INVESTORS LP (US$435.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BMRN
- PRIMECAP MANAGEMENT CO/CA/ 14.19M sh · $811.96M · Q2 2026
- Viking Global Investors 7.62M sh · $435.82M · Q2 2026
- VIKING GLOBAL INVESTORS LP 7.62M sh · $435.82M · Q2 2026
- Vestal Point Capital, LP 6.03M sh · $344.75M · Q2 2026
- Deep Track Capital, LP 3.31M sh · $189.25M · Q2 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 111.50M sh · $108.89M · Q2 2026
More on BOONE CAPITAL MANAGEMENT LLC
FAQ
How long has BOONE CAPITAL MANAGEMENT LLC held BMRN?
BOONE CAPITAL MANAGEMENT LLC has disclosed BMRN holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
What is BOONE CAPITAL MANAGEMENT LLC's current position in BMRN?
As of Q2 2026, BOONE CAPITAL MANAGEMENT LLC holds 583.22K shares of BMRN (BIOMARIN PHARMACEUTICAL INC), valued at $33.37M, representing 7.81% of its reported portfolio and ranking #6.
Has BOONE CAPITAL MANAGEMENT LLC been buying or selling BMRN?
In the latest 13F filing (Q2 2026), BOONE CAPITAL MANAGEMENT LLC increased its position in BMRN. The position peaked in Q2 2026 at 583.22K shares.
Which other funds hold BMRN?
Other major institutional holders of BMRN include PRIMECAP MANAGEMENT CO/CA/, Viking Global Investors, VIKING GLOBAL INVESTORS LP, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.